Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Galectin Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00054977
First received: February 14, 2003
Last updated: March 9, 2012
Last verified: March 2012

February 14, 2003
March 9, 2012
February 2003
April 2005   (final data collection date for primary outcome measure)
Safety [ Time Frame: 60 days - two cycles of treatment ] [ Designated as safety issue: Yes ]
Safety
Complete list of historical versions of study NCT00054977 on ClinicalTrials.gov Archive Site
Tumor progression [ Time Frame: CT imaging at 60 days ] [ Designated as safety issue: No ]
Tumor progression
Not Provided
Not Provided
 
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors

This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.

5-Fluorouracil is a chemotherapy drug commonly used in cancer patients. Patients with different type of solid tumors who have failed standard, approved treatments can be enrolled in the study. Escalated doses of GM-CT-01 will be given alone in Cycle 1, and in combination with 5-fluorouracil in cycle 2. Patients will be on study for approximately 60 days for determination of safety. However, with patient consent treatment can continue until disease progression is determined by CT scan. The study secondary reason is to determine whether treatment has stabilize the tumors or change it in size (get bigger, smaller or stay the same)after Cycle 2 and any additional cycles of treatment.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Drug: GM-CT-01
    IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
    Other Name: DAVANAT
  • Drug: 5-fluorouracil
    IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
    Other Name: 5-FU
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
September 2006
April 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject is able to give informed consent to participate in this trial (including all procedures and follow-up visits).
  • The subject is male or female at least 18 years of age.
  • The subject has a documented histologic or cytologic recurrent or metastatic solid tumor that is not amenable to curative surgery, radiotherapy, or conventional chemotherapy of proven value.
  • Subjects must have completed previous therapy (chemotherapeutic agents or other therapies including radiation) at least 4 weeks prior to study entry.
  • Following major surgery (e.g. laparotomy), > 4 weeks must have elapsed and subjects must have recovered from effects.
  • Following minor surgery (does not include insertion of vascular access device), > 2 weeks must have elapsed.
  • ECOG performance status of 0-2.
  • The subject has a life expectancy of at least 12 weeks.
  • Female subjects must be post-menopausal, surgically sterile, or using effective contraception.

Laboratory values prior to administration of study drug:

  • If female and not post-menopausal, the subject has a negative pregnancy test.
  • Liver function studies: AST and ALT < 2.5 times the upper limit of normal (ULN); total bilirubin < 1.5
  • Hematopoietic parameters: WBC > 3000 per mm3; Granulocyte count > 1,500 per mm3; Platelet count > 100,000 per mm3
  • Renal: Creatinine < or = ULN
  • Pulmonary: Dlco > or = 60% of predicted

Exclusion Criteria:

  • If female, the subject is pregnant or breast feeding.
  • Central nervous system (CNS) metastases or primary CNS tumors.
  • The subject has a known hypersensitivity to GM-CT-01 or any of its components.
  • The subject has congestive heart failure or any other medical condition that could be adversely affected by intravenous infusion of up to approximately 200 mL of fluid over 60 minutes.
  • The subject is currently abusing alcohol and/or illicit drugs.
  • The subject has other significant medical, psychiatric, or social conditions which, in the investigators' opinion, may compromise the subject's safety in participating in this study.
  • In the investigators' judgment, the subject would be unreliable in adhering to the study visit schedule or other study requirements.
  • The subject is currently enrolled in a clinical trial or has participated in a clinical trial within the 30 days prior to entry into this study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00054977
DAVFU-001
No
Galectin Therapeutics Inc.
Galectin Therapeutics Inc.
Not Provided
Study Director: Marilyn C Pike, M.D., Ph.D. Consultant to Pro-Pharmaceuticals, Inc.
Galectin Therapeutics Inc.
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP